Papers by Arzu Didem Yalçın
TURKISH JOURNAL OF MEDICAL SCIENCES, 2021
Background/aim: We aimed to report outcomes of pregnant patients with asthma under omalizumab tre... more Background/aim: We aimed to report outcomes of pregnant patients with asthma under omalizumab treatment and their infants in our country. Materials and methods: Patients with asthma who received omalizumab for at least 6 months and at least one dose during their pregnancy were retrospectively evaluated using a questionnaire regarding their disease and therapy and the health of their infants. Results: Twenty pregnant patients and their 23 infant's data were analyzed. The mean delivery age was 31.8 ± 7.4 years. They received omalizumab for 28.9 ± 21.8 months. Eight (36.4%) patients showed exacerbation of the disease during pregnancy. Forced expiratory volume in 1 s (FEV1) and asthma control test (ACT) scores at the starting time of omalizumab administration, first month of the pregnancy, and after delivery were 71 ± 18%, 83.4 ± 10.5%, and 80.5 ± 13% (FEV1), and 11.9 ± 4.9, 20.2 ± 2.6, and 20.4 ± 2.2 (ACT), respectively. One patient gave birth to twin infants, two patients to two infants each in different years, and 17 to one infant each. Three (13%) infants had low birth weight and five (21.7%) were born prematurely. No congenital anomalies were detected. Seven (30.4%) infants presented atopic diseases during their life. Conclusion: Omalizumab treatment during pregnancy seems to be safe for both patients and their infants.
Archives of Clinical and Medical Case Reports, 2020
A prospective multicenter study reported safety of omalizumab in pregnant asthmatics. However, re... more A prospective multicenter study reported safety of omalizumab in pregnant asthmatics. However, real life data about
Immunopharmacology and Immunotoxicology, 2020
The SARS-CoV-2 is a b-CoV, which is enveloped by non-segmented positive-stranded RNA vir€ us. Whe... more The SARS-CoV-2 is a b-CoV, which is enveloped by non-segmented positive-stranded RNA vir€ us. When b-CoV infects the respiratory tract, it can cause mild and/or severe acute respiratory syndrome (SARS) with consequent release of cytokines/mediators, including interleukin (IL)
World Allergy Organization Journal, 2015
Background Recently it has been suggested that, the worldwide increase in allergic diseases such ... more Background Recently it has been suggested that, the worldwide increase in allergic diseases such asthma, allergic rhinitis and food allergy is associated with low serum vitamin D levels. The aim of this study was to measure serum vitamin D levels in patients with allergic rhinitis.
World Allergy Organization Journal, 2015
World Allergy Organization Journal, 2015
World Allergy Organization Journal, 2015
BMC infectious diseases, Jan 5, 2004
Common variable immunodeficiency syndrome predominantly affects adults. It is characterized by lo... more Common variable immunodeficiency syndrome predominantly affects adults. It is characterized by low production of all the major classes of immunoglobulins. We report a case of common variable immunodeficiency syndrome with right aortic arch. An association of right-sided arch and common variable immunodeficiency syndrome has not been previously reported. A 41-year-old female patient presented with a history of recurrent pneumonia, sinusitis, otitis media, diarrhoea, cystitis since childhood. Biochemical and immunocytochemical analysis revealed common variable immunodeficiency syndrome and radiological evaluation confirmed right aortic arch and aberrant left subclavian artery. Common variable immunodeficiency syndrome syndrome is a clinical entity that should be kept in mind in patients with recurrent infections of different sites.
World Allergy Organization Journal, 2012
eligible patients were challenged with antigen 27 minutes after dosing. To assess duration of act... more eligible patients were challenged with antigen 27 minutes after dosing. To assess duration of action, patients were challenged with allergen 16 hours after dosing. The percentage of eyes with zero itching in both studies was assessed at 3 minutes post allergen challenge. Results: The percentage of eyes with zero itch at the 3 minutes timepoint after the onset of action allergen challenge was 60.0% for OLO-treated eyes compared with 5.9% for vehicle-treated eyes (P , .0001, OLO vs vehicle). The percentage of eyes with zero itch at 3 minutes post allergen challenge following the 16-hour dosing was 59.8% for OLO-treated eyes compared with 22.0% for vehicle-treated eyes (P , .0001, OLO vs vehicle). Conclusions: In bilateral CAC studies, ocular itching was prevented in a higher percentage (P , .0001) of eyes treated with 0.2% olopatadine hydrochloride ophthalmic solution when compared with vehicle as early as 30 minutes and for at least 16 hours post dosing.
Journal of Allergy & Therapy, 2012
Background: The primary use of omalizumab (trade name Xolair) is for patients with severe, persis... more Background: The primary use of omalizumab (trade name Xolair) is for patients with severe, persistent and allergic asthma. Our aim was to evaluate the therapeutic efficacy of omalizumab as a treatment modality in patients with different allergic conditions. Methods: There were eleven patients, whom followed-up with omalizumab therapy in the Immunology-Allergy Clinic, were evaluated by the clinical findings of nasal polyposis, anaphylaxis history, drug allergy, latex allergy, food allergy, autoimmune urticaria, allergic rhino-conjunctivitis, atopic dermatitis, angioedema and venom allergy. Results: The patients, who had severe persistent asthma for periods ranging from 3 to 8 years, were enrolled in the study. Omalizumab was chosen as a potential new systemic therapy for the patients due to the clinical indication. Clinical symptoms of the all patients with severe persistent asthma were decreased. And in addition, asthma control test and pulmonary function tests were improved up. A severe anaphylactic reaction is prevented in a patient with 48 bee stings. Conclusion: This clinical follow-up of omalizumab treated patients with severe persistent asthma and many different allergic conditions, suggests omalizumab is an effective therapy for asthma and different allergic conditions.
BioMed Research International, 2015
Omalizumab depletes free IgE in the blood and interstitial space and inhibits IgE binding to FcεR... more Omalizumab depletes free IgE in the blood and interstitial space and inhibits IgE binding to FcεRI on basophils, mast cells, and dendritic cells. We stopped omalizumab treatment after four years. Recurrences of urticaria symptoms were found to be higher in patients with chronic urticaria than recurrences of asthmatic symptoms in severe persistent asthma patients. For the very first time, we used omalizumab in symptomatic therapy of recurrent laryngeal oedema and urticaria attacks in a patient with postoperative pulmonary carcinoid tumor for eight months. During the four years of follow-up, no recurrence was noted in pulmonary carcinoid tumor. Control PET CT results revealed normal findings. After omalizumab treatment, laryngeal oedema and urticaria symptoms were decreased. The most common adverse reaction from omalizumab is injection site induration, injection site itching, injection site pain, and bruising but the package insert contains warnings regarding parasitic infections. Whi...
Medical science monitor : international medical journal of experimental and clinical research, 2014
Omalizumab, a humanized mAb that binds to the CH3 domain near the binding site for the high-affin... more Omalizumab, a humanized mAb that binds to the CH3 domain near the binding site for the high-affinity type-I IgE Fc receptors of human IgE, can neutralize free IgE and inhibit the IgE allergic pathway without sensitizing mast cells and basophils. We found that omalizumab in patients with severe persistent asthma (SPA) was an effective therapy for asthma and the following co-morbid conditions: chronic urticaria (CU), bee venom allergy, latex allergy, atopic dermatitis, food allergy and Samter's syndrome. Information on the use of omalizumab in treatment of asthma and other allergic diseases has improved our understanding that treatment acts on many levels, including regulating levels of inflammatory proteins, including cytokines (copper-containing alpha- 2-glycoprotein, total antioxidant capacity, MDA, NO, H2O2, CXCL8, IL-10, TGF-β, GMCSF, IL-17, IL-1β), MPV, Hs-CRP, eosinophil cationic peptide, vitamin-D (25(OH)D), homocysteine (Hcy), OX-2, d- dimer, albumin, and sApo-2L. The dec...
World Allergy Organization Journal, 2017
patients and a marked decrease in expression of the uPA receptor by esophageal eosinophils. Genet... more patients and a marked decrease in expression of the uPA receptor by esophageal eosinophils. Genetic studies revealed epistasis between genetic variants in SPINK7 and PLAU (gene product, uPA) with atopy risk variants in ST2 and thymic stromal lymphopoietin (TSLP), respectively. Conclusions We propose that SPINK7 deficiency and uncontrolled protease activity serve a causative role in compromising the esophageal barrier. We suggest that SPINK7 represents a novel checkpoint in regulating innate immunity, and its deficiency, as occurs in EoE, induces proinflammatory and pro-allergic responses characterized by excessive cytokine production and epithelial barrier impairment, likely via a KLK-and uPA-dependent mechanism. Additionally, EoE disease susceptibility is influenced by genetic interactions between variants in this pathway (SPINK7 and PLAU) and cardinal atopy pathways (ST2 and TSLP).
World Allergy Organization Journal, 2013
Eurasian Journal of Pulmonology, 2017
Objective: The mechanism of biological treatment molecule called omalizumab used in asthma treatm... more Objective: The mechanism of biological treatment molecule called omalizumab used in asthma treatment is thought to be versatile; however, the mechanism still remains unknown. This study was undertaken in severe asthma patients underwent omalizumab treatment, in order to investigate the relationship between biomarker expression and disease characteristics related to the immune system. Methods: Consecutive patients with severe asthma disease (n=15; Group IA, pretreatment and Group IB, post-treatment) underwent omalizumab treatment. Control group was age-and sex-matched including 25 healthy in Group II. Blood samples from both the groups were taken during their first visit (Group IA and II) and then after 12 months of treatment in asthmatic patients (Group IB). Serum levels of homocysteine (Hcy), eosinophil cationic peptide (ECP), 25-hydroxyvitamin D (25(OH)D), interleukin-1β (IL-1β), soluble OX 2 (sCD200) and clinical follow-up tests including fractional exhaled nitric oxide (FeNO), asthma control test (ACT), and pulmonary function tests were evaluated. Results: After the treatment, 25(OH)D levels and pulmonary function tests, including forced expiratory volume in 1 second (FEV 1) and forced vital capacity (FVC) levels, were significantly increased. Furthermore, total immunoglobulin E (IgE), Hcy, ECP, FeNO, and sCD200 levels were dramatically diminished. Regression analysis revealed positive correlations between ACT-FEV 1 and ACT-FVC and between FeNO-age and FeNO-ECP for Group IA patients. Negative correlations were detected between ACT-IgE, age-FEV 1 , FeNO-FEV 1 , and Fe-NO-FVC for Group IA patients. Conclusion: Our results suggest that the potential use of serum biomolecules in concordance to the clinical status of the asthmatic patients might be a follow-up tool for the omalizumab therapy.
Eurasian Journal of Pulmonology, 2017
Objective: Immune responses can change with exercise. We aimed to show the changes in cytokine le... more Objective: Immune responses can change with exercise. We aimed to show the changes in cytokine levels pre-and post-exercise in patients with asthma. Methods: In this prospective control trial, data of 32 patients with asthma that was under control were classified into two groups, pre-and post-exercise. Serum IL-1β and monocyte IL-1β, IL-2, and IL-10 expressions were evaluated using enzyme-linked immunosorbent assay. The patients were advised to walk for at least 30 min for 4 days/week for 12 weeks. Results: There was no significant difference in demographic properties of the participants. Monocyte IL-1β levels in the pre-and post-exercise groups were 1.99±0.35 and 1.01±0.22 pg/mL, respectively (p=0.003). IL-10 levels in the pre-and post-exercise groups were 1.64±0.02 and 1.21±0.03 pg/mL, respectively (p=0.04). IL-2 levels in the pre-and post-exercise groups were 0.64±0.045 and 0.32±0.09 pg/mL, respectively (p=0.001). However, there was a significant difference in serum IL-1β and monocyte IL-1β, IL-2, and IL-10 levels between the groups (p=0.02, p=0.003, p=0.04, and p=0.001, respectively). Conclusion: Systemic inflammatory parameters that are commonly elevated in asthma may improve by exercise. The elucidation of the mechanism of immune control in patients with asthma is useful for the future treatment of asthma.
World Allergy Organization Journal, 2013
Journal of B.U.ON. : official journal of the Balkan Union of Oncology
The purpose of this study was to evaluate the soluble Apo-2L (sApo-2L) levels in the ascitic flui... more The purpose of this study was to evaluate the soluble Apo-2L (sApo-2L) levels in the ascitic fluid and to study its potential in detecting malignant ascites and soluble CD200 (sCD200,sOX-2) levels so as to predict its clinical usage for detecting stage 4 metastatic endometrial, ovarian and breast cancer in serum samples. Ascitic fluid from 53 and blood from 25 subjects without known malignancy on admission were collected. There were 14 breast cancer (BC), 17 ovarian cancer (OC) and 19 endometrial cancer (EC) patients diagnosed later on. Blood samples for sApo-2L, sCD200, liver function tests and CEA, CA-19.9 and CA-125 were always taken and assayed in the morning. Significantly low levels of sApo-2L were observed in peritoneal fluid from OC and EC patients compared to benign peritoneal fluid from control individuals. Positive correlation was observed between sApo-2L and aspartate aminotransferase (AST) in benign peritoneal fluid and sCD200, and creatinine and sCD200 and platelets in...
Uploads
Papers by Arzu Didem Yalçın